GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Cyclically Adjusted PS Ratio

SLN (Silence Therapeutics) Cyclically Adjusted PS Ratio : 5.21 (As of May. 10, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Cyclically Adjusted PS Ratio?

As of today (2025-05-10), Silence Therapeutics's current share price is $3.70. Silence Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $0.71. Silence Therapeutics's Cyclically Adjusted PS Ratio for today is 5.21.

The historical rank and industry rank for Silence Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

SLN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.22   Med: 24   Max: 142.14
Current: 3.61

During the past years, Silence Therapeutics's highest Cyclically Adjusted PS Ratio was 142.14. The lowest was 2.22. And the median was 24.00.

SLN's Cyclically Adjusted PS Ratio is ranked better than
58.93% of 504 companies
in the Biotechnology industry
Industry Median: 5.14 vs SLN: 3.61

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Silence Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2024 was $0.515. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.71 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Silence Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Cyclically Adjusted PS Ratio Chart

Silence Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.40 39.57 14.90 6.04 9.76

Silence Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.04 28.26 25.73 23.81 9.76

Competitive Comparison of Silence Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Silence Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Silence Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Silence Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.70/0.71
=5.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Silence Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.515/135.1000*135.1000
=0.515

Current CPI (Dec. 2024) = 135.1000.

Silence Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 0.000 88.900 0.000
201006 0.000 90.200 0.000
201012 0.000 91.700 0.000
201106 0.000 93.500 0.000
201112 0.000 95.000 0.000
201206 0.000 95.600 0.000
201212 0.000 97.300 0.000
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 0.000 99.800 0.000
201412 0.000 99.900 0.000
201506 0.000 100.100 0.000
201512 0.000 100.400 0.000
201606 0.000 101.000 0.000
201612 0.000 102.200 0.000
201706 0.000 103.500 0.000
201712 0.000 105.000 0.000
201806 0.000 105.900 0.000
201812 0.000 107.100 0.000
201906 0.000 107.900 0.000
201912 0.000 108.500 0.000
202006 0.000 108.800 0.000
202009 0.093 109.200 0.115
202012 0.124 109.400 0.153
202103 0.150 109.700 0.185
202106 0.125 111.400 0.152
202109 0.142 112.400 0.171
202112 0.156 114.700 0.184
202203 0.251 116.500 0.291
202206 0.148 120.500 0.166
202209 0.114 122.300 0.126
202212 0.207 125.300 0.223
202303 0.392 126.800 0.418
202306 0.318 129.400 0.332
202309 0.092 130.100 0.096
202312 0.083 130.500 0.086
202403 0.356 131.600 0.365
202406 0.016 133.000 0.016
202409 0.032 133.500 0.032
202412 0.515 135.100 0.515

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Silence Therapeutics  (NAS:SLN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Silence Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.